VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
About VistaGen Therapeutics, Inc.
- NASDAQ: $VTGN
- Notified: $0.62
- 08:02 EDT
